

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions of claims in the application.

1-12. (Cancelled)

13. (Currently Amended) A method of screening for a substance which improves arteriosclerosis
~~a vascular cell disorder~~ which occurs due to the function of Rac protein, comprising:

adding a test substance to a first HUVEC culture which expresses a Rac fusion protein
comprising a HUVEC-expressing fluorescent protein, which contains a labelled Rac protein,

culturing a second HUVEC culture which expresses the Rac fusion protein comprising
the HUVEC-expressing fluorescent protein,

continuously culturing said first HUVEC culture and said second HUVEC culture for a
sufficient time for the Rac fusion protein to transfer into the nucleus, said first HUVEC culture
being continuously cultured in the presence of the test substance and said second HUVEC
culture being continuously cultured in the absence of the test substance,

measuring distribution of the amount of fluorescence in the transfer of the labelled Rac
protein into the nucleus of said first HUVEC culture and said second HUVEC culture, and

determining that the test substance is a substance which improves arteriosclerosis ~~the~~
~~vascular cell disorder~~ which occurs due to the function of Rac protein if the distribution of
fluorescence in the nucleus of said first HUVEC culture is greater than the distribution of

fluorescence in the nucleus of said second HUVEC culture by a significant amount ~~transfer of the labelled Rac protein into the nucleus of said HUVEC is visually identified.~~

14-15. (Cancelled)

16. (Currently Amended) The screening method according to claim 13, ~~or 14,~~ wherein said first HUVEC culture and said second HUVEC culture are cultured for measuring of the transfer of the labelled Rac protein is performed 15 hours prior to said measuring distribution of the amount of fluorescence in said first HUVEC culture and said second HUVEC culture after said test substance is added to said HUVEC.

17-20. (Cancelled)

21. (Currently Amended) A method of screening for a substance which inhibits the function of Rac protein, comprising:

adding a test substance to a first HUVEC culture which expresses a Rac fusion protein comprising a HUVEC-expressing fluorescent protein, which contains a labelled Rac protein;

culturing a second HUVEC culture which expresses the Rac fusion protein comprising a HUVEC-expressing fluorescent protein,

continuously culturing said first HUVEC culture and said second HUVEC culture for a sufficient time for the Rac fusion protein to transfer into the nucleus, said first HUVEC culture

being continuously cultured in the presence of the test substance and said second HUVEC culture being continuously cultured in the absence of the test substance,

measuring distribution of the amount of fluorescence in ~~the transfer of the labelled Rae protein into the nucleus of~~ said first HUVEC culture and said second HUVEC culture, and

determining that the test substance is a substance which inhibits the function of Rac protein if the distribution of fluorescence in the nucleus of said first HUVEC culture is greater than the distribution of fluorescence in the nucleus of said second HUVEC culture by a significant amount ~~transfer of the labelled Rae protein into the nucleus of said HUVEC is visually identified~~

wherein the function of Rac is signal transmission mediated by angiotensin II, PDGF, thrombin, endothelin and leukotriene B4 in vascular walls and promotion of activity of NADPH.

22-23. (Cancelled)

24. (Currently Amended) The screening method according to claim 21, ~~or 22~~; wherein said first HUVEC culture and said second HUVEC culture are cultured for ~~measuring of the transfer of the labelled Rae protein is performed~~ 15 hours prior to said measuring distribution of the amount of fluorescence in said first HUVEC culture and said second HUVEC culture ~~after said test substance is added to said HUVEC.~~

25. (Cancelled)